- Home
- AIRI vs NERV Comparison
AIRI vs NERV Comparison
Compare AIRI & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRI
- NERV
- Stock Information
- Founded
- AIRI 1979
- NERV 2007
- Country
- AIRI United States
- NERV United States
- Employees
- AIRI N/A
- NERV N/A
- Industry
- AIRI Military/Government/Technical
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- AIRI Industrials
- NERV Health Care
- Exchange
- AIRI Nasdaq
- NERV Nasdaq
- Market Cap
- AIRI 15.2M
- NERV 14.6M
- IPO Year
- AIRI N/A
- NERV 2014
- Fundamental
- Price
- AIRI $3.17
- NERV $2.18
- Analyst Decision
- AIRI
- NERV Hold
- Analyst Count
- AIRI 0
- NERV 1
- Target Price
- AIRI N/A
- NERV $5.00
- AVG Volume (30 Days)
- AIRI 43.2K
- NERV 16.8K
- Earning Date
- AIRI 11-13-2025
- NERV 11-04-2025
- Dividend Yield
- AIRI N/A
- NERV N/A
- EPS Growth
- AIRI N/A
- NERV N/A
- EPS
- AIRI N/A
- NERV 1.48
- Revenue
- AIRI $52,277,000.00
- NERV N/A
- Revenue This Year
- AIRI N/A
- NERV N/A
- Revenue Next Year
- AIRI $3.53
- NERV N/A
- P/E Ratio
- AIRI N/A
- NERV $1.42
- Revenue Growth
- AIRI N/A
- NERV N/A
- 52 Week Low
- AIRI $2.80
- NERV $1.15
- 52 Week High
- AIRI $6.41
- NERV $2.83
- Technical
- Relative Strength Index (RSI)
- AIRI 52.72
- NERV 52.97
- Support Level
- AIRI $3.03
- NERV $2.06
- Resistance Level
- AIRI $3.18
- NERV $2.15
- Average True Range (ATR)
- AIRI 0.10
- NERV 0.12
- MACD
- AIRI 0.01
- NERV -0.01
- Stochastic Oscillator
- AIRI 72.92
- NERV 50.00
About AIRI Air Industries Group
Air Industries Group is an aerospace and defense company. Its manufactures and designs structural parts and assemblies that focus on flight safety, including landing gear, arresting gear, engine mounts, flight controls, throttle quadrants, jet engines, and other components. The company also provides sheet metal fabrication of aerostructures, tube bending, and welding services.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.